nebulized pulmonary drug delivery

AACT, Inc. is a research-and-development-stage biopharmaceutical company focused on oncology, developing small-molecule, patent-protected drugs that exploit biological differences between tumor and normal cells. Its technology derives from research at the Icahn School of Medicine at Mount Sinai and the Fels Institute for Cancer Research and Molecular Biology of Temple University School of Medicine. Lead candidates include AA150030 and AA108600. AACT also runs an antiviral program developing broad-spectrum host-directed antivirals.

Read more

drug discoverykinase inhibitor developmentmedicinal chemistrypreclinical testing